Yahoo Web Search

Search results

1. • Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Rises By 6.2%

     ETF DAILY NEWS· 1 day ago

     Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling ...

2. • 

     Clearside Biomedical stock target cut, maintains Buy rating By Investing.com

     Investing.com· 4 days ago

     On Monday, Clearside Biomedical (NASDAQ:CLSD) saw its price target adjusted by H.C. Wainwright. The...

3. • 

     Best Ads of the Week: Coi Leray kicks it with Foot Locker & Dove decodes mom life with AI

     The Drum· 2 days ago

     This week, Editora Taverna fought the good fight against gay conversion therapy Brazil, Vivo rallied...

4. • Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress

     GuruFocus.com via Yahoo Finance· 7 days ago

     Its flagship product, ADVM-022 (Ixo-vec), aims to revolutionize care for patients with wet age-related macular degeneration (AMD) by reducing the frequency ...

5. • 

     Meet Dr. Chris Vincent, see the MyEyeDr. difference at Avery Ranch

     Community Impact· 5 days ago

     MyEyeDr. is committed to helping patients live their best lives by providing patients with...

6. • 

     Indoor tanning beds and eyelash extensions: are they safe for teenagers? | Expert Opinion

     Philly.com· 5 days ago

     Now that the school year is ending soon and wardrobes are changing from puffy coats to prom dresses,...

7. • StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

     ETF DAILY NEWS· 4 days ago

     StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report published on Friday morning. The firm issued a sell rating on the biopharmaceutical company ...

8. • Study: For treating retinopathy of prematurity, UB-led research proves that ranibizumab is safe

     UB Reporter· 7 days ago

     ROP occurs in low birthweight premature babies; if not treated, it can lead to blindness. The study, published in eClinicalMedicine online before print on April 11, answers a longstanding concern ...

9. • Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) to Post FY2028 Earnings of $0.16 Per Share, HC...

     ETF DAILY NEWS· 3 days ago

     Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report) – Investment analysts at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for shares of Lineage Cell Therapeutics ...

10. • Small Business - The Andalusia Star-News | The Andalusia Star-News

      The Andalusia Star-News· 3 days ago

      All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets